US52886X1072 - Common Stock
LEXEO THERAPEUTICS INC
NASDAQ:LXEO (12/23/2024, 10:37:17 AM)
6.27
-0.01 (-0.16%)
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The company is headquartered in New York City, New York and currently employs 58 full-time employees. The company went IPO on 2023-11-03. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
LEXEO THERAPEUTICS INC
345 Park Avenue South, Floor 6
New York City NEW YORK
P: 12125479879
Employees: 69
Website: https://www.lexeotx.com/
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer...
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results...
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's...
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference...
Here you can normally see the latest stock twits on LXEO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: